相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。FOXP3+Treg as a therapeutic target for promoting anti-tumor immunity
Theresa L. Whiteside
EXPERT OPINION ON THERAPEUTIC TARGETS (2018)
Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy
Benjamin J. Wolf et al.
FRONTIERS IN IMMUNOLOGY (2018)
CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
Lisa A. King et al.
FRONTIERS IN IMMUNOLOGY (2018)
A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients
Olivier Gasser et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Dual Modifications of alpha-Galactosylceramide Synergize to Promote Activation of Human Invariant Natural Killer T Cells and Stimulate Anti-tumor Immunity
Divya Chennamadhavuni et al.
CELL CHEMICAL BIOLOGY (2018)
Regulatory T cells in cancer immunotherapy
Atsushi Tanaka et al.
CELL RESEARCH (2017)
Dendritic cells combined with tumor cells and α-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma
Laura Escriba-Garcia et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2017)
Targeting iNOS to increase efficacy of immunotherapies
Suhendan Ekmekcioglu et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)
Harnessing the Power of Invariant Natural Killer T Cells in Cancer Immunotherapy
Melissa Bedard et al.
FRONTIERS IN IMMUNOLOGY (2017)
Mixed Signals: Co-Stimulation in invariant Natural Killer T Cell-Mediated Cancer immunotherapy
Susannah C. Shissler et al.
FRONTIERS IN IMMUNOLOGY (2017)
Natural Killer T Cells in Cancer immunotherapy
Shiny Nair et al.
FRONTIERS IN IMMUNOLOGY (2017)
New Directions for Natural Killer T Cells in the Immunotherapy of Cancer
Luc Teyton
FRONTIERS IN IMMUNOLOGY (2017)
Co-delivery of the NKT agonist -galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses
Reem Ghinnagow et al.
ONCOIMMUNOLOGY (2017)
Co-delivery of tumor-derived exosomes with alpha-galactosylceramide on dendritic cell-based immunotherapy for glioblastoma
Hongyu Liu et al.
CANCER LETTERS (2017)
Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial
Mark A. Exley et al.
CLINICAL CANCER RESEARCH (2017)
A Subset of CD8αβ+ Invariant NKT Cells in a Humanized Mouse Model
Xiangshu Wen et al.
JOURNAL OF IMMUNOLOGY (2015)
Genetic engineering of hematopoietic stem cells to generate invariant natural killer T cells
Drake J. Smith et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Synthetic TRP2 long-peptide and α-galactosylceramide formulated into cationic liposomes elicit CD8+ T-cell responses and prevent tumour progression
Silke Neumann et al.
VACCINE (2015)
NKT cell-dependent glycolipid-peptide vaccines with potent anti-tumour activity
Regan J. Anderson et al.
CHEMICAL SCIENCE (2015)
Inhibition of iNOS activity enhances the anti-tumor effects of alpha-galactosylceramide in established murine cancer model
Hiroyasu Ito et al.
ONCOTARGET (2015)
Stimulation of invariant natural killer T cells by α-Galactosylceramide activates the JAK-STAT pathway in endothelial cells and reduces angiogenesis in the 5T33 multiple myeloma model
Haneen Nur et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma
Joshua Richter et al.
BLOOD (2013)
CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses
Stephanie Corgnac et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Synergistic Induction of Adaptive Antitumor Immunity by Codelivery of Antigen with α-Galactosylceramide on Exosomes
Ulf Gehrmann et al.
CANCER RESEARCH (2013)
Administration of anti-CD25 mAb leads to impaired α-galactosylceramide-mediated induction of IFN-γ production in a murine model
Rodney A. Rosalia et al.
IMMUNOBIOLOGY (2013)
Human CD1d knock-in mouse model demonstrates potent antitumor potential of human CD1d-restricted invariant natural killer T cells
Xiangshu Wen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
NKT cells as an ideal anti-tumor immunotnerapeutic
Shin-ichiro Fujii et al.
FRONTIERS IN IMMUNOLOGY (2013)
Humanizing mice for the identification of novel anticancer lipids targeting iNKT cells
Xiangshu Wen et al.
ONCOIMMUNOLOGY (2013)
NKT-cell-based immunotherapies in clinical trials
Mark A. Exley et al.
CLINICAL IMMUNOLOGY (2011)
Galactose-modified iNKT cell agonists stabilized by an induced fit of CD1d prevent tumour metastasis
Sandrine Aspeslagh et al.
EMBO JOURNAL (2011)
The stimulating adventure of KRN 7000
Aline Banchet-Cadeddu et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2011)
Analysis of the CD1 Antigen Presenting System in Humanized SCID Mice
Jennifer L. Lockridge et al.
PLOS ONE (2011)
Presumed guilty: natural killer T cell defects and human disease
Stuart P. Berzins et al.
NATURE REVIEWS IMMUNOLOGY (2011)
Potent anti-tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand
Troels R. Petersen et al.
IMMUNOLOGY AND CELL BIOLOGY (2010)
Differential Recognition of CD1d-α-Galactosyl Ceramide by the Vβ8.2 and Vβ7 Semi-invariant NKT T Cell Receptors
Daniel G. Pellicci et al.
IMMUNITY (2009)
Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells
Tonya J. Webb et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2009)
PD-1/PD-L Blockade Prevents Anergy Induction and Enhances the Anti-Tumor Activities of Glycolipid-Activated Invariant NKT Cells
Vrajesh V. Parekh et al.
JOURNAL OF IMMUNOLOGY (2009)
Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induced antitumor effects in mice
Kathrin Stirnemann et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Enhanced suppression of pulmonary metastasis of malignant melanoma cells by combined administration of alpha-galactosylceramide and interleukin-18
Shoji Nishio et al.
CANCER SCIENCE (2008)
Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell-mediated immunity via dendritic cells
Kanako Shimizu et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Regulation by Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 of α-galactosylceramide-induced antimetastatic activity and Th1 and Th2 responses of NKT cells
Jun Okajo et al.
JOURNAL OF IMMUNOLOGY (2007)
Tumor cells loaded with α-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice
Kanako Shimizu et al.
JOURNAL OF IMMUNOLOGY (2007)
Hyporesponsiveness to natural killer T-cell ligand α-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide
Kazuhiko Yanagisawa et al.
CANCER RESEARCH (2006)
CD1d expression level in tumor cells is an important determinant for anti-tumor immunity by natural killer T cells
Kyoko Haraguchi et al.
LEUKEMIA & LYMPHOMA (2006)
Dendritic cells pulsed with alpha-galactosylceramide induce anti-tumor immunity against pancreatic cancer in vivo
S. Nagaraj et al.
INTERNATIONAL IMMUNOLOGY (2006)
Cooperation of invariant NKT cells and CD4+ CD25+ T regulatory cells in the prevention of autoimmune myasthenia
RL Liu et al.
JOURNAL OF IMMUNOLOGY (2005)
Targeted expression of human CD1d in transgenic mice reveals independent roles for thymocytes and thymic APCs in positive and negative selection of vα14i NKT cells
J Schümann et al.
JOURNAL OF IMMUNOLOGY (2005)
Therapeutic effect of α-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells
H Matsuyoshi et al.
CANCER SCIENCE (2005)
Glycolipid antigen induces long-term natural killer T cell anergy in mice
VV Parekh et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
The crystal structure of human CD1d with and without α-galactosylceramide
M Koch et al.
NATURE IMMUNOLOGY (2005)
Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients
DH Chang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Activated CD1d-restricted natural killer T cells secrete IL-2:: innate help for CD4+CD25+ regulatory T cells?
SP Jiang et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes:: results of thefirst phase I clinical trial
B Escudier et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2005)
A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer
MA Morse et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2005)
Human invariant Vαa24-JαQ TCR supports the development of CD1d-dependent NK1.1+ and NK1.1- T cells in transgenic mice
M Capone et al.
JOURNAL OF IMMUNOLOGY (2003)
Prolonged IFN-γ-producing NKT response induced with α-galactosylceramide-loaded DCs
S Fujii et al.
NATURE IMMUNOLOGY (2002)
Sequential production of interferon-γ by NK1.1+ T cells and natural killer cells is essential for the antimetastatic effect of α-galactosylceramide
MJ Smyth et al.
BLOOD (2002)
Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by α-galactosylceramide in mice
R Nakagawa et al.
JOURNAL OF IMMUNOLOGY (2001)
Human CD1d functions as a transplantation antigen and a restriction element in mice
B Wang et al.
JOURNAL OF IMMUNOLOGY (2001)
分享论文
